⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APGE News
Apogee Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
APGE
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results
globenewswire.com
APGE
Apogee Therapeutics to Participate in Upcoming March Conferences
globenewswire.com
APGE
Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
prnewswire.com
AMGN
CNTB
NKTR
APGE
LLY
OGN
ABBV
PFE
REGN
INCY
Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook: Biotech Summit 2026
globenewswire.com
APGE
Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook
globenewswire.com
APGE
Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026
globenewswire.com
APGE
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
globenewswire.com
APGE
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
globenewswire.com
APGE
Apogee Therapeutics to Participate in Upcoming Conferences
globenewswire.com
APGE